journal
MENU ▼
Read by QxMD icon Read
search

Melanoma Research

journal
https://www.readbyqxmd.com/read/28207426/psychological-characteristics-of-early-stage-melanoma-patients-a-cross-sectional-study-on-204-patients
#1
Valentina Tesio, Simone Ribero, Lorys Castelli, Stefania Bassino, Paolo Leombruni, Virginia Caliendo, Marcella Grassi, Danilo Lauro, Giuseppe Macripò, Riccardo G V Torta
The presence of psychological distress has a negative impact not only on cancer patients' quality of life but also on the course of the disease, with slower recovery and increased morbidity. These issues are of particular importance in melanoma patients (MP), who remain at risk of disease progression for many years after diagnosis. This study aimed to investigate psychological distress, coping strategies, and their possible relationships with demographic-clinical features in patients with early-stage melanoma in follow-up...
February 15, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28151776/lymph-nodes-capsular-naevi-are-associated-with-high-naevus-count-in-melanoma-patients-a-case-control-study
#2
Simone Ribero, Caterina Longo, Francesca Specchio, Simonetta Piana, Fabio Castagnetti, Elvira Moscarella, Aimilios Lallas, Roberto Alfano, Giuseppe Argenziano
Capsular naevi (CNs) in lymph nodes (LNs) are relatively common, occurring in 3-22% of patients who undergo LN surgery for melanoma. Naevus count is one of the principal risk factors for melanoma, as well as a prognostic factor in melanoma patients. However, little is known about the occurrence of CN in melanoma patients on the basis of their naevus count. A case-control study was performed, to look at the naevus count differences between CN-positive and CN-negative melanoma patients. Cases (CN positive) were matched for age, sex and Breslow thickness with controls (CN negative)...
February 1, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28146044/checkpoint-inhibitor-associated-drug-reaction-with-eosinophilia-and-systemic-symptom-syndrome
#3
Sayeef Mirza, Ebone' Hill, Steven P Ludlow, Sowmya Nanjappa
Drug reaction with eosinophilia and systemic symptom syndrome is a potentially fatal drug reaction that must be recognized quickly. Ipilimumab and nivolumab are both important agents in the treatment of melanoma and continue to be studied in other malignancies. We believe the mainstay of therapy for immunotherapy-induced drug reaction with eosinophilia and systemic symptom syndrome is early recognition, discontinuation of the inciting agent, supportive care, and treatment with high dose corticosteroids with appropriate tapers that may reduce the length of internal organ injury in cases with liver or kidney involvement...
January 31, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28146043/characterization-of-melanoma-susceptibility-genes-in-high-risk-patients-from-central-italy
#4
Cristina Pellegrini, Maria Giovanna Maturo, Claudia Martorelli, Mariano Suppa, Ambra Antonini, Dimitra Kostaki, Lucilla Verna, Maria Teresa Landi, Ketty Peris, Maria Concetta Fargnoli
Genetic susceptibility to cutaneous melanoma has been investigated in Italian high-risk melanoma patients from different geographical regions. CDKN2A, CDK4, and MC1R genes have been screened in most studies, MITF and POT1 were screened in only one study, and none analyzed the TERT promoter. We carried out a mutational analysis of CDKN2A, CDK4 exon 2, POT1 p.S270N, MITF exon 10, MC1R, and the TERT promoter in 106 high-risk patients with familial melanoma (FM) and sporadic multiple primary melanoma (spMPM) from Central Italy and evaluated mutations according to the clinicopathological characteristics of patients and lesions...
January 31, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28099367/antiphospholipid-syndrome-associated-with-combined-immune-checkpoint-inhibitor-therapy
#5
Arjun Gupta, Udayan Shah, Htet Khine, Travis Vandergriff, Thomas Froehlich
No abstract text is available yet for this article.
January 31, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28125448/basal-neutrophil-to-lymphocyte-ratio-is-associated-with-overall-survival-in-melanoma
#6
Leonardo S Lino-Silva, Rosa A Salcedo-Hernández, Leticia García-Pérez, Abelardo Meneses-García, César Zepeda-Najar
Several studies have reported that a high neutrophil-to-lymphocyte ratio (NLR) is associated with poor clinical outcomes in several cancers, but this ratio has not been thoroughly studied in melanoma except in stage IV. This is the first study on NLR in melanoma stages I-III. This was a retrospective study of 742 melanoma patients. The NLR was classified into NLR<2 and a NLR≥2 on the basis of a receiver operating characteristic curve. Associations of NLR with clinicopathological characteristics and survival were examined...
January 25, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28125447/the-microenvironment-in-primary-cutaneous-melanoma-with-associated-spontaneous-tumor-regression-evaluation-for-t-regulatory-cells-and-the-presence-of-an-immunosuppressive-microenvironment
#7
Arielle Gray, Solomiya Grushchak, Kumaran Mudaliar, Stephanie Kliethermes, Kyle Carey, Kelli A Hutchens
Spontaneous tumor regression, regression in the absence of therapeutic intervention, can be identified histologically in over 25% of primary cutaneous melanomas at initial diagnosis. A unique subset of T lymphocytes found in areas of regression can be histologically distinguished from tumor-infiltrating T lymphocytes (TIL) found in areas of tumor progression. We call this unique subset of T lymphocytes regression-associated T lymphocytes (RATs). The aim of this study is to determine the phenotype of lymphocytes and the density of specific cell types linked to immunosuppression in areas of tumor progression compared with areas of tumor regression...
January 25, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28118270/the-heterogeneity-of-tumor-infiltrating-cd8-t-cells-in-metastatic-melanoma-distorts-their-quantification-how-to-manage-heterogeneity
#8
Joseph M Obeid, Yinin Hu, Gulsun Erdag, Katie M Leick, Craig L Slingluff
CD8 T-cell infiltration of metastatic melanoma may be a useful biomarker for prediction of prognosis and response to therapy. The heterogeneous distribution of CD8 T cells within a single tumor, and across different tumors within a single patient, may complicate quantification of infiltration. However, the impact of heterogeneity has not been quantified sufficiently. To address this, we have assessed intratumoral heterogeneity of CD8 T-cell counts, as well as intertumoral heterogeneity for synchronous and metachronous metastases...
January 21, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28118269/trends-in-hepatocyte-growth-factor-insulin-like-growth-factor-1-thyroid-stimulating-hormone-and-leptin-expression-levels-in-uveal-melanoma-patient-serum-and-tumor-tissues-correlation-to-disease-progression
#9
Junna Oba, Bita Esmaeli, Julie A Ellerhorst, Genevieve R Lyons, Denái R Milton, Wei-Lien Wang, Mariana P Macedo, Alexander J Lazar, Elizabeth A Grimm, Chandrani Chattopadhyay
This exploratory study was carried out to determine the expression levels of hepatocyte growth factor (HGF), insulin-like growth factor 1, thyroid-stimulating hormone (TSH), and leptin in serum and tumor samples from patients with uveal melanoma and to investigate the potential association of these expression levels with disease progression and patient survival. Seventeen patients, including nine nonmetastatic and eight metastatic, were included in the study. Eighteen healthy individuals served as controls...
January 21, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28099369/the-cessation-of-anti-pd-1-antibodies-of-complete-responders-in-metastatic-melanoma
#10
Rahul Ladwa, Victoria Atkinson
The optimal duration of PD-1 antibodies for metastatic melanoma is unknown. In previous trials, there has been the potential to cease therapy if the patient achieves a complete response (CR). We aimed to assess the outcomes of patients who had ceased anti-PD-1 antibodies in this setting. A retrospective review was carried out of CR to PD-1-based therapy across two institutions. Patients were from the Pembrolizumab Named Patient Program (PEM NPP), Nivolumab monotherapy (NIVO), and reimbursed Pembrolizumab (r PEM)...
January 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28099368/recurrence-behavior-in-early-stage-cutaneous-melanoma-pattern-timing-survival-and-influencing-factors
#11
Faruk Tas, Kayhan Erturk
Nearly one-third of all melanoma patients will experience disease recurrence and the majority of the relapses eventually develop metastatic disease as a consequence of disease progression in the early-stage melanoma patients. Although the factors that predict the recurrence have already been described, very few numbers of studies have investigated the natural recurrence history of melanoma. In this retrospective study, we analyzed the time until recurrence along with the patterns and outcomes of the recurrences; thus, we aimed to understand the possible factors that might influence the recurrence course in early-stage cutaneous melanoma at the first relapse...
January 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28099366/does-the-distribution-pattern-of-brain-metastases-during-braf-inhibitor-therapy-reflect-phenotype-switching
#12
Silvia A Haueis, Pascale Kränzlin, Joanna Mangana, Phil F Cheng, Mirjana Urosevic-Maiwald, Ralph P Braun, Mitchell P Levesque, Reinhard Dummer, Simone M Goldinger
Brain metastases (brain mets) are frequent in metastatic melanoma patients. The aim of this study was to investigate the morphology and progression pattern of brain mets in melanoma patients treated with BRAF inhibitors (BRAFi) compared with patients who did not receive targeted therapy (BRAFi group and control group). The number and size of brain mets were compared between a baseline and a comparative MRI at progression. The number of brain mets was grouped into seven number classes (N=1-4, N=5-10, N=11-20, N=21-30, N=31-40, N=41-50, and N>50) and its difference was reported as the change of class that occurred...
January 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28099365/melanoma-during-pregnancy-a-report-of-60-pregnancies-complicated-by-melanoma
#13
Jorine de Haan, Christianne A Lok, Christianne J de Groot, Marianne B Crijns, Kristel Van Calsteren, Karina Dahl Steffensen, Michael J Halaska, Sevilay Altintas, Ingrid A Boere, Robert Fruscio, Wojciech Kolawa, Petronella O Witteveen, Frédéric Amant
The management of melanoma during pregnancy is challenging as maternal benefits and fetal risks need to be balanced. Here, we present an overview of the incidence, the demographic and clinical characteristics and the treatment modalities used. After analysis of obstetric, fetal and maternal outcome, recommendations for clinical practice are provided. From the 'International Network on Cancer, Infertility and Pregnancy' database, pregnant patients with melanoma were identified and analysed. Sixty pregnancies were eligible for analysis...
January 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28079609/mesenchymal-stem-cells-induce-epithelial-mesenchymal-transition-in-melanoma-by-paracrine-secretion-of-transforming-growth-factor-%C3%AE
#14
Chuan Lv, Haiying Dai, Mengyan Sun, Hui Zhao, Kai Wu, Ji Zhu, Yuchong Wang, Xian Cao, Zhaofan Xia, Chunyu Xue
Mesenchymal stem cells (MSCs) are considered for potential use as an ideal vehicle to efficiently deliver therapeutic agents in treatment against cancers including melanoma. However, emerging evidence indicates that MSCs promote tumor growth and progression. Therefore, a comprehensive understanding of the role of MSCs is very important to evaluate the MSCs-based therapy in melanoma. B16 melanoma cells treated by MSC conditioned medium (CM), showed significantly enhanced migration and invasion, which was also confirmed in a lung metastasis mice model in vivo...
January 5, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28060055/genetic-counselling-and-high-penetrance-susceptibility-gene-analysis-reveal-the-novel-cdkn2a-p-d84v-c-251a-t-mutation-in-melanoma-prone-families-from-italy
#15
Riccardo G Borroni, Ausilia M Manganoni, Sara Grassi, Maurizia Grasso, Marta Diegoli, Carmela Giorgianni, Valentina Favalli, Laura Pavoni, Maddalena Cespa, Eloisa Arbustini
Genetic susceptibility to primary cutaneous melanoma (PCM) may account for up to 12% of PCMs, presenting as the familial atypical mole/multiple melanoma syndrome (FAMMM), an autosomal dominant condition with incomplete penetrance and variable expressivity, characterized by PCM in at least two relatives and/or more than one PCMs in the same patient. To identify individuals at high genetic risk of PCM, from 1 January 2012 to 31 December 2015, we offered genetic counselling and molecular analysis of the two high-penetrance FAMMM susceptibility genes, cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase 4 (CDK4), to 92 consecutive, unrelated patients with FAMMM...
January 4, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28030434/exhaustive-pathologic-work-up-in-sentinel-lymph-node-biopsy-for-melanoma-is-it-necessary
#16
Leonardo S Lino-Silva, Ana L Castillo-Medina, Rosa A Salcedo-Hernández, Leticia García-Pérez
The objective of this study is to determine whether a less exhaustive pathologic work-up to detect melanoma metastasis is clinically useful and does not affect patient prognosis. The success and evolution of the sentinel lymph node (SLN) depends on histological techniques. Several exhaustive protocols of SLN analysis have been published, but are time and cost consuming, with slight increases in the rates of metastasis detection. From 281 patients with SLN biopsy, each SLN was sectioned every 2 mm and from each paraffin block, 2-3 histological sections were evaluated...
December 27, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27997431/attenuation-of-genome-wide-5-methylcytosine-level-is-an-epigenetic-feature-of-cutaneous-malignant-melanomas
#17
Goran Micevic, Nicholas Theodosakis, Janis M Taube, Marcus W Bosenberg, Nemanja Rodić
Epigenetic modification of DNA, namely covalent changes of cytosine residues, plays a key role in the maintenance of inactive chromatin regions, both in health and in disease. In the vast majority of malignant melanomas, the most notable known epigenetic abnormality is the attenuation of 5-hydroxymethylcytosine (5-hmC) residues. However, it remains unknown whether a decrease in 5-hmC represents a primary defect of melanoma cancer epigenome or whether it is secondary to the loss of 5-methylcytosine (5-mC), a chemical substrate for 5-hmC...
December 16, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27977496/new-onset-third-degree-atrioventricular-block-because-of-autoimmune-induced-myositis-under-treatment-with-anti-programmed-cell-death-1-nivolumab-for-metastatic-melanoma
#18
Juliane Behling, Joachim Kaes, Thomas Münzel, Stephan Grabbe, Carmen Loquai
There has been considerable progress in treating malignant melanoma over the last few years. The immune-checkpoint-inhibitors nivolumab and pembrolizumab have been approved by the Food and Drug Administration in 2014 for the therapy of metastatic melanoma. Anti-programmed cell death-1-blocking antibodies are known to cause immune-related adverse events. Physicians should be aware of common and rare side effects and pay attention to new ones. We therefore report a severe and life-threatening side effect of anti-programmed cell death-1 immunotherapy with nivolumab that has not been previously reported: the development of a third-degree atrioventricular block...
December 13, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27926588/incidence-trends-and-clinical-pathological-characteristics-of-invasive-cutaneous-melanoma-from-1980-to-2010-in-the-canton-of-zurich-switzerland
#19
Remo Minini, Sabine Rohrmann, Ralph Braun, Dimitri Korol, Silvia Dehler
The aims of this paper are to describe the incidence trends of invasive cutaneous melanoma in the Canton of Zurich and to evaluate clinical and pathological factors such as cancer subtype, localization, age and Breslow thickness. A retrospective analysis was carried out with data from the population-based Cancer Registry of Zurich and Zug located in Zurich. A total of 8469 cases in 8034 different patients of invasive cutaneous melanoma were registered for the period 1980-2010 in the Canton of Zurich. Incidence trends were age standardized to the European standard population...
December 6, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27926587/anti-programmed-cell-death-protein-1-tolerance-and-efficacy-after-ipilimumab-immunotherapy-observational-study-of-39-patients
#20
Reyhan Amode, Barouyr Baroudjian, Anita Kowal, Majdi Jebali, Clara Allayous, Martine Bagot, Nika Madjlessi, Jennifer Roux, Manuelle Viguier, Nicole Basset Seguin, Raphaël Porcher, Cécile Pagès, Céleste Lebbé
In patients with ipilimumab (IPI)-refractory melanoma, the anti-programmed cell death proteins 1 (PD1s) nivolumab (NIV) and pembrolizumab (PEM) are considered to be a new standard of treatment. Few data are available on anti-PD1 safety in patients who develop IPI-related severe adverse events (AEs) (grade≥3). The aim of this study was to compare the anti-PD1 safety and efficacy in patients with previous severe toxicity to IPI versus in those showing moderate and no previous IPI-related AEs. This single institution-based observational study included all patients treated with anti-PD1 (PEM or NIV) and previously treated with IPI for unresectable stage III or IV melanoma...
December 6, 2016: Melanoma Research
journal
journal
30785
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"